A noncontagious, chronic, multisystem disease.
Initial symptoms are nonspecific and include fatigue, vague musculoskeletal complaints, diffuse swelling of hands, and Raynaud phenomenon.
Etiology and pathogenesis are unknown.
Disease course is variable, but the condition rarely subsides spontaneously.
There are two main subtypes of systemic sclerosis (SSc): limited cutaneous SSc and diffuse cutaneous SSc. The limited cutaneous form tends to have less severe internal organ involvement and a better prognosis, but these subjects still need to be followed closely for possible complications.
Clinical course is determined by extent of vascular and fibrosing complications. Vascular involvement includes Raynaud phenomenon, ischemic digital ulcers, hypertensive crisis, and pulmonary arterial hypertension. Fibrosis can involve lungs, heart, and GI tract.
Treatment is targeted on disease processes that are potentially reversible (e.g., active inflammation or vasoconstriction) and aims to minimize functional impairment of the patient.
Systemic sclerosis (SSC), also known as scleroderma, is a multisystem, autoimmune disease, characterized by functional and structural abnormalities of small blood vessels, fibrosis of skin and internal organs, and production of autoantibodies.
History and exam
- Raynaud phenomenon
- digital pits or ulcers
- swelling of the hands and feet
- skin thickening
- loss of function of hands
- heartburn, reflux, and dysphagia
- fecal incontinence
- arthralgias and myalgias
- abnormal nail-fold capillaroscopy
- subcutaneous calcinosis
- dry crackles at lung bases
- tendon friction rub
- abrupt onset moderate/marked hypertension
Professor of Medicine
Division of Rheumatology and Clinical Immunogenetics
University of Texas Health Science Center
Houston Medical School
MDM is an advisory board member for Boehringer-Ingelheim, Genentech and Astellas. She receives royalties from Oxford University Press for "The Scleroderma Book: A guide for patients and families". MDM is an author of a number of references cited in this monograph.
Dr Maureen D. Mayes would like to gratefully acknowledge Dr Rajpreet K. Arora-Singh, a previous contributor to this monograph. RKA declares that she has no competing interests.
Associate Professor of Medicine
Department of Rheumatology
Medical College of Wisconsin
MEC has been reimbursed by: Actelion International (and is a member of its speakers bureau); Encysive Pharmaceuticals; and MediQuest Therapeutics. She is local principal investigator for the SCOT trial, sponsored by NIH.
Division of Rheumatic and Autoimmune Diseases
Department of Medicine
University of Minnesota
JM declares that he has no competing interests.
Department of Rheumatology
Newcastle Upon Tyne
BG declares that she has no competing interests.
Reader in Rheumatology and Consultant Rheumatologist
Musculoskeletal Research Group
University of Manchester
ALH declares that she has no competing interests.
Use of this content is subject to our disclaimer